Claims for Patent: 5,102,652

Summary for Patent: 5,102,652

Title:	Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
Abstract:	This invention relates to compositions comprising a colloidal or particular metal oxide which are stabilized by low molecular weight carbohydrates. The carbohydrates are characterized by the fact that a) they are not retained on the surface of the metal oxide based on the equilibrium room temperature dialysis of about 2 ml of the metal oxide composition at 0.2 M metal concentration against deionized water; and b) they impart sufficient stability to the metal oxide compositions such that the compositions can withstand heat stress without perceptible aggregation as determined by a prescribed test procedure.
Inventor(s):	Groman; Ernest V. (Brookline, MA), Josephson; Lee (Arlington, MA)
Assignee:	Advanced Magnetics Inc. (Cambridge, MA)
Application Number:	07/475,618
Patent Claims:	1. An improved MR contrast agent composition parenterally administrable to an animal or human subject, comprising (a) a biodegradable superparamagnetic metal oxide coated by or associated with a polymeric substance in a physiologically acceptable carrier, which metal oxide is capable of being biodegraded by said subject within about 2 weeks or less after administration, as evidenced by a return of proton relaxation rates of an affected organ or tissue of said subject to preadministration levels; and (b) mannitol at a concentration between about 0.001M and about 2M. 2. An improved parenterally administrable composition, comprising a colloidal or particular biodegradable superparamagnetic metal oxide coated by or associated with a high molecular weight polymeric substance in a physiologically acceptable carrier, which metal oxide is capable of being biodegraded by a subject within about two weeks or less after administration, as evidenced by a return of proton relaxation rates of an affected organ or tissue of said subject to preadministration levels and is filterable through a 0.8 micron filter, wherein the improvement comprises the addition to said carrier of: an effective amount of a stabilizer which comprises a physiologically acceptable, soluble, low molecular weight carbohydrate, which carbohydrate (a) is not retained on the surface of said metal oxide based on the equilibrium room temperature dialysis of about 2 ml of said composition at 0.2M metal concentration against deionized water; and (b) imparts improved physical stability to said composition as determined by heating said composition at about 55.degree. C. for about 3 days and then filtering said composition through a 0.8 micron filter, whereafter substantially no precipitate is visible on said filter. 3. An improved parenterally administrable composition, comprising a colloidal or particular biodegradable superparamagnetic metal oxide coated by or associated with a polymeric substance in a physiologically acceptable carrier, which metal oxide is capable of being biodegraded by a subject within about two weeks or less after administration, as evidenced by a return of proton relaxation rates of an affected organ or tissue of said subject to preadministration levels and is filterable through a 0.8 micron filter, wherein the improvement comprises the addition to said carrier of: an effective amount of a stabilizer which comprises a physiologically acceptable, soluble, low molecular weight carbohydrate, which carbohydrate (a) is not retained on the surface of said metal oxide based on the equilibrium room temperature dialysis of about 2 ml of said composition at 0.02M metal concentration against deionized water; and (b) imparts improved physical stability to said composition as determined by autoclaving said composition at about 121.degree. C. for about 30 minutes and then filtering said composition through a 0.8 micron filter, whereafter substantially no precipitate is visible on said filter. 4. The composition of claim 2 or 3 wherein said metal is selected from the group consisting of chromium, cobalt, iron, manganese and mixtures thereof. 5. The composition of claim 2 or 3 in which the low molecular weight carbohydrate is present at a concentration of about 0.001M to about 2M. 6. The composition of claim 2 or 3 wherein said low molecular weight carbohydrate has a molecular weight below 5,000 daltons. 7. The composition of claim 6 wherein said low molecular weight carbohydrate is linear polyalcohol carbohydrate. 8. The composition of claim 7 wherein said linear polyalcohol carbohydrate is selected from the group consisting of mannitol, sorbitol and glycerol. 9. The composition of claim 6 wherein said low molecular weight carbohydrate is inositol. 10. The composition of claim 2 or 3 wherein said low molecular weight carbohydrate is dextran having a molecular weight of about 1,000 daltons. 11. The composition of claim 2 or 3 wherein said low molecular weight carbohydrate is mannitol. 12. The composition of claim 2 or 3 wherein said low molecular weight carbohydrate is ascorbate. 13. The composition of claim 2 or 3 in which said carrier comprises a buffer. 14. The composition of claim 2 or 3 in which said carrier further comprises a preservative. 15. The composition of claim 2 or 3 in which said high molecular weight polymer is selected from the group consisting of dextran having a molecular weight of about 5,000 to about 500,000 daltons, starch having a molecular weight of about 5,000 to about 500,000 daltons, polysaccharide having a molecular weight of about 5,000 to about 500,000 daltons, bovine serum albumin and organosilane. 16. The composition of claim 2 or 3 in which said colloid or particulate biodegradable superparamagnetic metal oxide is selected from the group consisting of a dextran-magnetite, a magnetic carbohydrate matrix type particle and an albumin microsphere. 17. The composition of claim 2 or 3 in which said metal is iron. 18. A method for obtaining an in vivo MR image of an organ or tissue of an animal or human subject which comprises parenterally administering to such subject the composition of claim 2 or 3. 19. A method for reducing anemia in an animal or human subject which comprises parenterally administering to such subject the composition of claim 17. 20. A method for stabilizing a biodegradable superparamagnetic metal oxide composition comprising a colloidal or particulate metal oxide coated by or associated with a high molecular weight polymeric substance in a liquid carrier, which metal oxide is capable of being biodegraded by a subject within about two weeks or less after administration, as evidenced by a return of proton relaxation rates of an affected organ or tissue of said subject to preadministration levels and which method comprises adding an effective amount of a stabilizer to said carrier which stabilizer comprises a soluble, low molecular weight carbohydrate, which carbohydrate (a) is not retained on the surface of said metal oxide based on the equilibrium room temperature dialysis of about 2 ml of said composition at 0.2M metal concentration against deionized water; and (b) imparts stability to said composition as determined by heating said composition at about 55.degree. C. for about 3 days and then filtering said composition through a 0.8 micron filter, whereafter o precipitate is visible on said filter. 21. A method for stabilizing a biodegradable superparamagnetic metal oxide composition comprising a colloidal or particulate metal oxide coated by or associated with a high molecular weight polymeric substance in a liquid carrier, which metal oxide is capable of being biodegraded by a subject within about two weeks or less after administration, as evidenced by a return of proton relaxation rates of an affected organ or tissue of said subject to preadministration levels and which method comprises adding an effective amount of a stabilizer to said carrier which stabilizer comprises a soluble, low molecular weight carbohydrate, which carbohydrate (a) is not retained on the surface of said metal oxide based on the equilibrium room temperature dialysis of about 2 ml of said composition at 0.2M metal concentration against deionized water; and (b) imparts stability to said composition as determined by autoclaving said composition at about 121.degree. C. for about 30 minutes and then filtering said composition through a 0.8 micron filter, whereafter no precipitate is visible on said filter. 22. The method of claim 20 or 21 wherein said metal oxide composition is selected from the group consisting of parenterally administrable MR contrast agent compositions, parenterally administrable compositions for reducing anemia and ferrofluids.